Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis

References

• United States Food and Drug Administration. FDA approves Entyvio to treat ulcerative colitis and Crohn’s disease. 2014. [cited 2016 Jan 15]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398065.htm.
   Google Scholar
• Fiorino G, Correale C, Fries W, et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul;6(4):567–572.
   PubMed Web of Science ®Google Scholar
• Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007 Apr;13(4):481–489.
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30;330(26):1841–1845.
   PubMed Web of Science ®Google Scholar
• Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002 Sep;8(5):317–324.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000543.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000544.
   PubMedGoogle Scholar
• Goldstein F, DiMarino AJ Jr. Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease. J Clin Gastroenterol. 2000 Jul;31(1):60–62.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa study group. Am J Gastroenterol. 1993 Aug;88(8):1188–1197.
   PubMed Web of Science ®Google Scholar
• Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC maintenance study group. Dig Dis Sci. 1995 Feb;40(2):296–304.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007 May;13(5):629–638.
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–599; quiz 600.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010 Mar;105(3):501–523; quiz 24.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001 May;48(5):591–592.
   PubMed Web of Science ®Google Scholar
• Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut. 2006 Apr;55(4):437–441.
   PubMed Web of Science ®Google Scholar
• McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol. 2014 Mar;8(3):223–240.
   PubMed Web of Science ®Google Scholar
• Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257-65e1-3.
   Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95; quiz e14–e15.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96–109e1.
   PubMed Web of Science ®Google Scholar
• Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009 Nov;68(11):1739–1745.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003 Feb 13;348(7):601–608.
   PubMed Web of Science ®Google Scholar
• Das P, Johnson MW, Tekkis PP, et al. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2007 Jan;9(1):15–27.
   PubMed Web of Science ®Google Scholar
• Wu H, Shen B. Pouchitis and pouch dysfunction. Gastroenterol Clin North Am. 2009 Dec;38(4):651–668.
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864–875.
   PubMed Web of Science ®Google Scholar
• Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997 Jul;151(1):97–110.
   PubMed Web of Science ®Google Scholar
• Hamann A, Andrew DP, Jablonski-Westrich D, et al. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol. 1994 Apr 1;152(7):3282–3293.
   PubMed Web of Science ®Google Scholar
• McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012 Sep;4(9):883–898.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International nonproprietary names for pharmaceutical substances. WHO Drug Inform. 2008;22(4):312–367.
   Google Scholar
• Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996 Nov;111(5):1373–1380.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005 Jun 16;352(24):2499–2507.
   PubMed Web of Science ®Google Scholar
• Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012 Aug;18(8):1470–1479. doi:10.1002/ibd.21896. Epub 2011 Dec 6.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EPAR summary for the public: Entyvio. 2014. [cited 2016 Jan 15]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002782/human_med_001751.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Feagan BG, McDonald JW, Greenberg GR, et al. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis. Gastroenterology. 2000;118(Suppl):A874.
   Google Scholar
• McLean LP, Cross RK. Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2016 Mar;25(3):263–273.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1370–1377.
   PubMed Web of Science ®Google Scholar
• Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012 Aug;18(8):1470–1479.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. An open-label study of vedolizumab (MLN0002) in patients with ulcerative colitis and Crohn’s disease (GEMINI LTS). 2016. [cited 2016 Jan 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT00790933.
   Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011 Jan-Feb;3(1):76–99.
   PubMed Web of Science ®Google Scholar
• Muldowney L. Center for drug evaluation and research [Internet]. Application number 125476Orig1s000. Med Rev. 2014. [cited 2016 May 3]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125476Orig1s000MedR.pdf
   Google Scholar
• Takeda Pharmaceuticals America Incorporated. Entyvio prescribing information. 2014. [cited 2016 Apr 1]. Available from: http://general.takedapharm.com/content/file.aspx?FileTypeCode=ENTYVIOPI&cacheRandomizer=ce2114e0-e03a-410c-919d-12618f98e15e.
   Google Scholar
• Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol. 2012 Feb;12(1):25–35.
   PubMedGoogle Scholar
• Health Canada. Entyvio. 2016. [cited 2016 Jan 3]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2015_entyvio_169414-eng.php.
   Google Scholar
• Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther. 2015 Jun;41(12):1227–1236.
   PubMed Web of Science ®Google Scholar